ADMA · Adma Biologics, Inc.
$9.47
+0.06 (+0.64%)
At close · Aug 14
Market Cap
$2.12B
Shares
223.98M
Adma Biologics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Adma Biologics, Inc. (ADMA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲98.7%
$41.09M
−$14.90M
'22 Q3
22-11-09
▲89.4%
$49.98M
−$12.23M
'22 Q4
23-03-23
▲95.6%
$56.91M
−$6.79M
'23 Q1
23-05-10
▲77.3%
$60.12M
−$6.37M
'23 Q2
23-08-09
▲63.7%
$67.28M
$2.56M
'23 Q3
23-11-08
▲47.9%
$73.90M
−$17.64M
'23 Q4
24-01-08
▲43.9%
$81.88M
$17.81M
'24 Q1
24-05-09
▲78.3%
$107.19M
$32.06M
'24 Q2
24-08-08
▲78.1%
$119.84M
$35.91M
'24 Q3
24-11-07
▲59.1%
$117.55M
$111.90M
'24 Q4
25-03-03
▲40.2%
$114.80M
$26.90M
'25 Q1
25-05-07
▲13.8%
$121.98M
$34.22M
'25 Q2
25-08-06
▲12%
$134.22M
$36.43M
'25 Q3
25-11-05
▲18.4%
$139.16M
$49.38M
'25 Q4
26-02-25
▼0.3%
$114.49M
$45.33M
'26 Q1
26-05-06
LATEST
▲2%
$124.39M
$37.82M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Adma Biologics, Inc. Q2 FY2026 Earnings Call
Revenue
$124.39M
▲ 2% YoY Diluted EPS
$0.16
▲ 14.3% YoY Gross margin
69.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Adma Biologics, Inc. Q1 FY2026 Earnings Call
Positive tone
Ascentive demand growth
Pediatric label expansion
Vivigam competitive pressure
Revenue
$114.49M
▼ 0.3% YoY Diluted EPS
$0.19
▲ 72.7% YoY Gross margin
70.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Adma Biologics, Inc. Q4 FY2025 Earnings Call
Confident tone
Financial results and profitability
Ascentive product growth and demand
Yield-enhanced manufacturing
Revenue
$139.16M*
▲ 18.4% YoY Gross margin
63.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Adma Biologics, Inc. Q3 FY2025 Earnings Call
Confident tone
ASCENIV growth and prescriber adoption
Financial performance and profitability
Capital deployment and guidance
Revenue
$134.22M
▲ 12% YoY Diluted EPS
$0.15
▲ 0% YoY Gross margin
56.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Adma Biologics, Inc. Q2 FY2025 Earnings Call
Confident tone
Revenue Growth & Financial Performance
Yield Enhancement / Manufacturing Efficiency
Facility Expansion & Capacity Planning
Revenue
$121.98M
▲ 13.8% YoY Diluted EPS
$0.14
▲ 7.7% YoY Gross margin
55.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Adma Biologics, Inc. Q1 FY2025 Earnings Call
Confident tone
Revenue Growth and Guidance
ASCENIV Franchise and Durability
Yield Enhancement Production Process
Revenue
$114.80M
▲ 40.2% YoY Diluted EPS
$0.11
▲ 37.5% YoY Gross margin
53.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Adma Biologics, Inc. Q4 FY2024 Earnings Call
Confident tone
Revenue and earnings momentum
ASCENIV product growth and market penetration
Enhanced yield production process (regulatory)
Revenue
$117.55M*
▲ 59.1% YoY Gross margin
53.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Adma Biologics, Inc. Q3 FY2024 Earnings Call
Confident tone
ASCENIV Commercial Momentum
Yield Enhancement Initiative
Revenue and Earnings Growth
Revenue
$119.84M
▲ 78.1% YoY Diluted EPS
$0.15
▲ 1400% YoY Gross margin
49.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Adma Biologics, Inc. Q2 FY2024 Earnings Call
Confident tone
ASCENIV demand and penetration
Raised financial guidance
Revenue growth and milestone
Revenue
$107.19M
▲ 78.3% YoY Diluted EPS
$0.13
Gross margin
53.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Adma Biologics, Inc. Q1 FY2024 Earnings Call
Confident tone
Asceniv commercial momentum
Post-2025 outlook uncertainty
Revenue growth and outperformance
Revenue
$81.88M
▲ 43.9% YoY Diluted EPS
$0.08
Gross margin
47.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Adma Biologics, Inc. Q4 FY2023 Earnings Call
Confident tone
Forward Guidance / Outlook
ASCENIV Product Performance
Revenue and Earnings Growth
Revenue
$73.90M*
▲ 47.9% YoY Gross margin
42.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Adma Biologics, Inc. Q3 FY2023 Earnings Call
Revenue
$67.28M
▲ 63.7% YoY Diluted EPS
$0.01
Gross margin
36.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Adma Biologics, Inc. Q2 FY2023 Earnings Call
Revenue
$60.12M
▲ 77.3% YoY Diluted EPS
$-0.03
Gross margin
27.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Adma Biologics, Inc. Q1 FY2023 Earnings Call
Revenue
$56.91M
▲ 95.6% YoY Diluted EPS
$-0.03
Gross margin
29.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Adma Biologics, Inc. Q4 FY2022 Earnings Call
Revenue
$49.98M*
▲ 89.4% YoY Gross margin
28.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Adma Biologics, Inc. Q3 FY2022 Earnings Call
Revenue
$41.09M
▲ 98.7% YoY Diluted EPS
$-0.08
Gross margin
23.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Adma Biologics, Inc. Q2 FY2022 Earnings Call
Revenue
$33.91M
▲ 90.2% YoY Diluted EPS
$-0.07
Gross margin
22.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Adma Biologics, Inc. Q1 FY2022 Earnings Call
Revenue
$29.10M
▲ 81.3% YoY Diluted EPS
$-0.13
Gross margin
12.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-19
Adma Biologics, Inc. Q4 FY2021 Earnings Call
Revenue
$26.38M*
▲ 89% YoY Gross margin
13.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-20
Adma Biologics, Inc. Q3 FY2021 Earnings Call
Revenue
$20.68M
▲ 101.2% YoY Diluted EPS
$-0.13
Gross margin
1.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Adma Biologics, Inc. Q2 FY2021 Earnings Call
Revenue
$17.83M
▲ 129% YoY Diluted EPS
$-0.15
Gross margin
-5.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Adma Biologics, Inc. Q1 FY2021 Earnings Call
Revenue
$16.05M
▲ 57.3% YoY Diluted EPS
$-0.16
Gross margin
-10.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Adma Biologics, Inc. Q4 FY2020 Earnings Call
Revenue
$13.96M*
▲ 15.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Adma Biologics, Inc. Q3 FY2020 Earnings Call
Revenue
$10.28M
▲ 42.3% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Adma Biologics, Inc. Q2 FY2020 Earnings Call
Revenue
$7.79M
▲ 18.7% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Adma Biologics, Inc. Q1 FY2020 Earnings Call
Revenue
$10.20M
▲ 189.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-13
Adma Biologics, Inc. Q4 FY2019 Earnings Call
Revenue
$12.04M*
▲ 196.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
1368514
CUSIP
000899104
13F (30d)
292 filings
288 filers
Visit website
Investor relations